Liminatus Pharma LIMN
NASDAQ LIMN
$3.24 +0.12 (+3.83%)
As of: Oct 22, 2026 · 9:40 AM EDT

Liminatus Pharma (LIMN) EBIT (2024 - 2026)

Updated

Liminatus Pharma (LIMN) reported EBIT of -$1.38 million for Q2 2026, compared with -$1.12 million a year earlier.

Analysis

Liminatus Pharma (LIMN) EBIT (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Liminatus Pharma's EBIT came in at -$4.07 million; for FY2025, it was -$2.97 million.

  • By year, EBIT came in at -$3.33 million in FY2024.
  • The Q2 2026 figure ranks as the lowest quarterly EBIT in data going back to Q2 2024.
  • Per Business Quant data, the three quarters before Q2 2026 came in at -$1.1 million (Q1 2026), -$884,211 (Q4 2025) and -$701,170 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Eli Lilly 1,148.13 Bn 1,116.72 Bn 19.71 Bn 11.75 Bn
2 Johnson & Johnson 630.09 Bn 548.62 Bn 17.26 Bn 7.14 Bn
3 AbbVie 498.99 Bn 472.10 Bn 12.70 Bn 6.43 Bn
4 Merck 374.92 Bn 329.30 Bn 12.21 Bn -584.00 Mn
5 Novartis Ag 300.99 Bn 264.98 Bn 11.24 Bn 4.75 Bn
6 Astrazeneca 264.63 Bn 238.32 Bn 12.86 Bn 3.16 Bn
7 Amgen 239.15 Bn 194.55 Bn 7.24 Bn 3.51 Bn
8 Gilead Sciences 192.23 Bn 166.43 Bn 6.22 Bn -10.39 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 4.27 Bn
10 Liminatus Pharma 3.14 Mn -2.85 Mn - -1.38 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.38 Mn
Mar 31, 2026 -1.10 Mn
Dec 31, 2025 -884,211.00
Sep 30, 2025 -701,170.00
Jun 30, 2025 -1.12 Mn
Mar 31, 2025 -264,220.00
Dec 31, 2024 -167,077.00
Sep 30, 2024 -543,147.00
Jun 30, 2024 -909,218.00
API Access

Liminatus Pharma EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=LIMN&period=max&api_key=YOUR_API_KEY